IRISH MEDICINES BOARD

Notice Information: Human Medicines - Advisory 24 January 2008

Part 1. Product Information

a)	Title:	EMEA recommends the approval of thalidomide for the treatment of multiple myeloma (rare bone-marrow cancer)
b)	Product Name/Type:	Thalidomide Pharmion
c)	Active Substance:	Thalidomide

Part 2. Problem/Issue

a)	Problem/Issue:	The European Medicines Agency (EMEA) has recommended approval of Thalidomide Pharmion across the EU for the treatment of multiple myeloma, a rare form of bone marrow cancer. Subject to granting of the market authorization by the European Commission, treatment with Thalidomide Pharmion should only be initiated and monitored by doctors with experience in the treatment of multiple myeloma. A risk management plan that includes actions to prevent pregnancy in women treated with thalidomide and exposure of their unborn children has been approved. Educational materials for healthcare professionals and patients will be provided about the treatment related risks and the precautions required to ensure safe use of the product. For further information, Please click here: Press Release

Part 3. Keywords

a)	Keywords:	thalidomide